Boston Scientific Corporation

NYSE:BSX

Medical - Devices

Healthcare
$43.64 +1.00%

+$0.45 today

Market cap
$63.25B
Beta
0.56
P/E (TTM)
19.0
EPS (TTM)
$2.39
52W Low $44.44High $109.50

Volume 13.21M

Average 19.45M

BSX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Boston Scientific CorporationNYSE: BSX

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $87M rose 16.0% year over year, ahead of the +5.7% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +10.8% a year.

Context

  • Stock-based compensation amounted to 1.5% of revenue in FY2025, unchanged from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +16.0% holds above the trailing-twelve-month pace of +5.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$87M— QoQ
Last fiscal yearDec 2025
$299M+12.4% YoY
LTMJun 2026
$166M+5.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.0%——
1 year+12.4%——
3-year CAGR+10.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
299M USD
Year-over-year change
+12.4%
4-year CAGR
+11.4%

Stock-Based Compensation vs competitors

How BSX compares with its peers on the latest reported figures

  • BSX's LTM Jun 2026 stock-based compensation of $166M is the 3rd largest of the 11 companies compared; the peer median is $46.33M.
  • Its year-over-year change of +5.7% is the 7th highest of 11, against a peer median of +12.2%.
  • Stock-based compensation amounts to 0.8% of revenue for BSX, versus a peer median of 3.0%.
BSX Competitors Peer median
Stock-Based Compensation for BSX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$496M +14.8%+8.8%1.3%
EWEdwards Lifesciences CorporationLTM Jun 2026$168M -1.5%+7.6%2.6%
BSXBoston Scientific CorporationLTM Jun 2026$166M +5.7%+10.8%0.8%
PENPenumbra, Inc.LTM Jun 2026$59.5M +16.5%—4.0%
LIVNLivaNova PLCLTM Sep 2026$49.04M +44.9%-6.8%3.3%
ATRCAtriCure, Inc.LTM Jun 2026$47.27M +13.2%+15.8%8.3%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$45.39M +5.4%+34.1%2.8%
TFXTeleflex IncorporatedLTM Jun 2026$20.21M -33.5%—0.8%
CNMDCONMED CorporationLTM Mar 2026$19.96M -39.8%+9.2%1.5%
ANGOAngioDynamics, Inc.LTM Feb 2026$11.69M +16.5%-3.0%3.7%
CVRXCVRx, Inc.LTM Mar 2026$11.51M +11.1%+41.7%19.5%
Peer median (excluding BSX) $46.33M+12.2%+9.0%3.0%

Competitors are the stored peer set for BSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income1.04B698M1.59B1.85B2.89B
Depreciation & Amortization1.09B1.14B1.2B1.27B1.37B
Deferred Income Tax(124M)(63M)(1M)(70M)(2M)
Stock-Based Compensation194M220M233M266M299M
Change in Working Capital(351M)(1.01B)(770M)(462M)(246M)
Accounts Receivables(279M)(220M)(238M)(351M)(269M)
Inventory(346M)(321M)(660M)(228M)(188M)
Accounts Payables408M(255M)118M243M296M
Other Working Capital(134M)(209M)10M(126M)(85M)
Other Non-Cash Items18M540M253M586M223M
Operating Cash Flow1.87B1.53B2.5B3.44B4.53B
Capital Expenditures(554M)(612M)(800M)(790M)(876M)
Acquisitions (Net)(1.43B)(1.54B)(1.81B)(4.64B)(1.59B)
Purchases of Investments96M(24M)000
Sales of Investments294M56M000
Other Investing Activities(1M)106M(52M)(257M)(171M)
Investing Cash Flow(1.6B)(2.01B)(2.57B)(5.69B)(2.64B)
Debt Repayment0(165M)(4M)1.83B(491M)
Common Stock Issued110M0182M230M282M
Common Stock Repurchased0136M000
Dividends Paid(55M)(55M)(28M)00
Other Financing Activities(150M)(464M)(145M)(243M)(186M)
Financing Cash Flow(95M)(548M)5M1.81B(395M)
Effect of Forex Changes(8M)(9M)(16M)(11M)42M
Net Change in Cash171M(1.04B)(82M)(449M)1.54B
Free Cash Flow1.32B914M1.7B2.65B3.66B

Boston Scientific Corporation

NYSE:BSX

Intrinsic Alpha fair value

Locked

Current Price

$43.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.